G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 8.18 HKD -0.24% Market Closed
Market Cap: 29B HKD

Net Margin
Grand Pharmaceutical Group Ltd

17.8%
Current
21%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.8%
=
Net Income
2.1B
/
Revenue
11.7B

Net Margin Across Competitors

No Stocks Found

Grand Pharmaceutical Group Ltd
Glance View

Market Cap
28.6B HKD
Industry
Pharmaceuticals

Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.

Intrinsic Value
6.55 HKD
Overvaluation 20%
Intrinsic Value
Price
G
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.8%
=
Net Income
2.1B
/
Revenue
11.7B
What is the Net Margin of Grand Pharmaceutical Group Ltd?

Based on Grand Pharmaceutical Group Ltd's most recent financial statements, the company has Net Margin of 17.8%.

Back to Top